Accuray (ARAY) to Post Quarterly Earnings on Wednesday

Posted by George Bondi on Aug 10th, 2026

Accuray (NASDAQ:ARAY – Get Free Report) will likely be announcing its Q4 2026 results after the market closes on Wednesday, August 12th. Analysts expect Accuray to announce earnings of ($0.03) per share and revenue of $105.30 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 19, 2026 at 4:30 PM ET.

Accuray Stock Performance

Shares of NASDAQ ARAY opened at $0.28 on Monday. The firm’s 50-day moving average price is $0.29 and its 200-day moving average price is $0.42. Accuray has a 52-week low of $0.22 and a 52-week high of $2.10. The company has a market cap of $33.90 million, a PE ratio of -0.77 and a beta of 1.39. The company has a quick ratio of 0.66, a current ratio of 1.42 and a debt-to-equity ratio of 3.21.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ARAY. AQR Capital Management LLC raised its holdings in Accuray by 762.3% in the 1st quarter. AQR Capital Management LLC now owns 162,922 shares of the medical equipment provider’s stock worth $292,000 after purchasing an additional 144,029 shares during the period. Jane Street Group LLC grew its holdings in Accuray by 429.3% during the first quarter. Jane Street Group LLC now owns 91,944 shares of the medical equipment provider’s stock valued at $165,000 after purchasing an additional 74,574 shares during the period. Geode Capital Management LLC increased its position in Accuray by 7.8% in the second quarter. Geode Capital Management LLC now owns 2,421,724 shares of the medical equipment provider’s stock worth $3,318,000 after buying an additional 174,703 shares in the last quarter. Marshall Wace LLP purchased a new stake in Accuray in the second quarter worth about $820,000. Finally, Sei Investments Co. raised its stake in shares of Accuray by 83.0% in the second quarter. Sei Investments Co. now owns 93,843 shares of the medical equipment provider’s stock worth $129,000 after buying an additional 42,557 shares during the period. 64.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ARAY has been the topic of a number of research analyst reports. Jefferies Financial Group downgraded shares of Accuray from a “buy” rating to a “hold” rating in a research report on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Accuray in a research note on Tuesday, August 4th. Finally, BTIG Research reissued a “neutral” rating on shares of Accuray in a report on Wednesday, July 8th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $2.00.

Check Out Our Latest Report on ARAY

About Accuray

(Get Free Report)

Accuray Incorporated (NASDAQ: ARAY) is a global medical device company that develops, manufactures and markets innovative radiation therapy solutions for the treatment of cancer. The company’s flagship products include the CyberKnife® System, a robotic radiosurgery platform offering sub-millimeter precision, and the TomoTherapy® System, which combines helical computed tomography (CT) imaging with intensity-modulated radiation therapy (IMRT). More recently, Accuray introduced the Radixact® System, an advanced iteration of its TomoTherapy technology designed to enhance treatment speed and clinical workflow.

Accuray’s suite of products enables clinicians to deliver highly targeted radiation doses while minimizing exposure to surrounding healthy tissue.